These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 11802627)

  • 1. Metabolic complications of HIV infection: translating research findings into clinical practice.
    Currier J
    AIDS Clin Care; 2002 Jan; 14(1):1-2, 8. PubMed ID: 11802627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current concepts of metabolic abnormalities in HIV patients: focus on lipodystrophy.
    Kolter DP
    AIDS Read; 2003 Dec; 13(12 Suppl):S5-13. PubMed ID: 14959694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse drug reactions to protease inhibitors.
    Manchanda T; Schiedel D; Fischer D; Dekaban GA; Rieder MJ
    Can J Clin Pharmacol; 2002; 9(3):137-46. PubMed ID: 12422251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Metabolic abnormalities in patients with HIV infection].
    Rodríguez-Carranza SI; Aguilar-Salinas CA
    Rev Invest Clin; 2004; 56(2):193-208. PubMed ID: 15377073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical management of HIV-associated lipodystrophy.
    Pirmohamed M
    Curr Opin Lipidol; 2009 Aug; 20(4):309-14. PubMed ID: 19494771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic disorders and cardiovascular risk in HIV-infected patients treated with antiretroviral agents.
    Fantoni M; Del Borgo C; Autore C; Barbaro G
    Ital Heart J; 2002 May; 3(5):294-9. PubMed ID: 12066561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.
    Falutz J
    Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Facial lipodystrophy in patients with HIV infections troublesome to treat].
    Walther RA
    Lakartidningen; 2002 Sep; 99(39):3826-9. PubMed ID: 12395531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AACTG recommendations for metabolic problems. Guide covers insulin resistance and diabetes.
    AIDS Alert; 2003 Jan; 18(1):6. PubMed ID: 12541993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
    Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
    AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The latest word on lipodystrophy and mitochondrial toxicity (and old words that still resound).
    Mascolini M
    IAPAC Mon; 2002 Jan; 8(1):14-32. PubMed ID: 11858198
    [No Abstract]   [Full Text] [Related]  

  • 15. Lipodystrophy in patients with HIV-1 infection: effect of stopping protease inhibitors on TNF-alpha and TNF-receptor levels, and on metabolic parameters.
    Maher B; Lloyd J; Wilkins EG; Fraser WD; Back D; Park BK; Pirmohamed M
    Antivir Ther; 2004 Dec; 9(6):879-87. PubMed ID: 15651746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New research confirms role of heart disease as a treatment by-product.
    AIDS Alert; 2003 Jan; 18(1):1, 4-6. PubMed ID: 12541992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection.
    Wainberg MA; Sawyer JP; Montaner JS; Murphy RL; Kuritzkes DR; Raffi F
    Antivir Ther; 2005; 10(1):13-28. PubMed ID: 15751760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.